NDAINTRAVENOUSEMULSION
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
SMOFLIPID 20% (smoflipid) by Fresenius Kabi is acids. Approved for malnutrition, parenteral nutrition associated cholestasis, essential fatty acid deficiency. First approved in 2016.
Drug data last refreshed 22h ago
Mechanism of Action
acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such…
Pharmacologic Class:
Lipid Emulsion
Indications (3)
Worked on SMOFLIPID 20% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.